NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

Similar documents
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Frequency of application of topical corticosteroids for atopic eczema

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

Drug misuse - opioid detoxification Stakeholder list

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Ovarian Cancer Guideline. Association of Chartered Physiotherapists in Oncology and Palliative Care

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description

National Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Pharmacologic Treatment of Atopic Dermatitis

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Low back pain and sciatica in over 16s NICE quality standard

WHO Framework Convention on Tobacco Control. Submission from the National Heart Forum (UK)

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Type 2 diabetes: the management of type 2 diabetes (update)

Study protocol. Version 1 (06 April 2011) Ethics ref: R&D ref: UK CRC portfolio ID:

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE

15 minute eczema consultation

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Single Technology Appraisal

Response to Scottish Government A Consultation on Electronic Cigarettes and Strengthening Tobacco Control in Scotland December 2014

Guideline scope Smoking cessation interventions and services

NAS NATIONAL AUDIT OF SCHIZOPHRENIA. Second National Audit of Schizophrenia What you need to know

Prostate Cancer Priority Setting Partnership. PROTOCOL June 2009

Technology appraisal guidance Published: 25 July 2007 nice.org.uk/guidance/ta123

Children and young people with cancer (quality standard) Stakeholder Abbott Molecular Action for Sick Children Acupuncture Association of Chartered

Technology appraisal guidance Published: 23 January 2008 nice.org.uk/guidance/ta134

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Methadone and buprenorphine for the management of opioid dependence

Single Technology Appraisal (STA) Tildrakizumab for treating moderate to severe plaque psoriasis

Appendix K Declarations of Interests

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE GUIDANCE EXECUTIVE (GE) Consideration of consultation responses on review proposal

Technology appraisal guidance Published: 26 March 2008 nice.org.uk/guidance/ta138

The audit is managed by the Royal College of Psychiatrists in partnership with:

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Technology appraisal guidance Published: 24 January 2007 nice.org.uk/guidance/ta116

Preventing the uptake of smoking by children

Dear Colleague SUPPLEMENTARY INFORMATION ON CANNABIS BASED PRODUCTS FOR MEDICINAL USE

How is the introduction of a new medicine regulated in the UK?

Dupixent (dupilumab)

Docetaxel for the adjuvant treatment of early node-positive breast cancer

A Guide to the Scottish Medicines Consortium

Area Drug and Therapeutics Committee Prescribing Supplement No 3 November 2003

Single Technology Appraisal (STA/MTA) Avelumab for treating metastatic Merkel cell carcinoma

Technology appraisal guidance Published: 26 September 2006 nice.org.uk/guidance/ta109

Single Technology Appraisal (STA) Adalimumab for treating moderate to severe hidradenitis suppurativa

Appendix D - NICE s response to consultee and commentator comments on the draft scope and provisional matrix

National Institute for Health and Care Excellence. Single Technology Appraisal (STA)

ROLE SPECIFICATION FOR MACMILLAN GPs

Technology appraisal guidance Published: 26 August 2009 nice.org.uk/guidance/ta177

Consultation on revised threshold criteria. December 2016

In 2017, we are proud to have supported the following patient organisations:

National Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)

Children s Hospital Of Wisconsin

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people

MS Priority Setting Partnership. PROTOCOL August 2012

Pandemic influenza Recommendations on the use of antiviral medicines for pregnant women, women who are breastfeeding and children under the age of

Appendix C - Summary form

MS Trust Comments on the ACD

EDINBURGH HEALTHCARE NHS TRUST. 4 Edinburgh Healthcare NHS Trust Printed Material,

Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015

Strategy for Personal and Public Involvement (PPI)

POSITION STATEMENT. Diabetic eye screening April Key points

GUIDELINES FOR THE MANAGEMENT OF PALLIATIVE CARE PATIENTS WITH A HISTORY OF SUBSTANCE MISUSE

Consent to research. A draft for consultation

Technology appraisal guidance Published: 24 February 2016 nice.org.uk/guidance/ta385

Managing knowledge to support appropriate use of health technologies: some insights from the UK National Health Service

WELSH HEALTH CIRCULAR

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)

Trabectedin for the treatment of relapsed ovarian cancer

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

National Institute for Health and Clinical Excellence. Peritoneal dialysis Pre publication check May 2011

NHS GG&C Introduction of Freestyle Libre flash glucose monitoring system

Appendix C Summary form

National Institute for Health and Clinical Excellence Health Technology Appraisal

WELSH GOVERNMENT RESPONSE TO RECOMMENDATIONS FROM THE HEALTH & SOCIAL CARE COMMITTEE: INQUIRY INTO NEW PSYCHOACTIVE SUBSTANCES

The National Assembly for Wales Health and Social Care Committee is undertaking an inquiry into access to medical technologies in Wales.

Engaging to Improve Access Zack Pemberton-Whiteley. Head of Campaigns and Advocacy Leukaemia CARE, UK

Alteplase for the treatment of acute ischaemic stroke. This guidance was developed using the single technology appraisal process

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Total Payment for sponsored attendances by Healthcare Professionals: 182,677 ( 153,923 in 2013)

TCIs are only available on prescription and are usually started by a dermatology specialist.

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal (STA)

17/09. NHSBT Board January Reports from the UK Health Departments. A report from each UK Health Department is attached.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Revised Standards. S 1a: The service routinely collects data on age, gender and ethnicity for each person referred for psychological therapy.

Dementia Priority Setting Partnership. PROTOCOL March 2012

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health

Compare your care. How asthma care in England matches up to standards R E S P I R AT O R Y S O C I E T Y U K

Transcription:

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Review proposal of NICE guidance no. 82; on the use of pimecrolimus and tacrolimus for atopic eczema Provisional matrix of consultees and commentators Manufacturers/sponsors Astellas Pharma Inc. (tacrolimus) Novartis Pharmaceuticals UK Ltd (pimecrolimus) Patient/carer groups Action Against Allergy Action for Sick Children Age Concern England Allergy UK Black Health Agency Changing Faces Chinese National Healthy Living Centre Confederation of Indian Organisations Counsel and Care Equalities National Council Help the Aged Muslim Council of Great Britain Muslim Health Network National Eczema Society Skin Care Campaign South Asian Health Foundation Specialised Healthcare Alliance WellChild Professional groups British Association for Services to the Elderly Commentators (no right to submit or appeal) General Age Concern Cymru Board of Community Health Councils in Wales British National Formulary Department of Health, Social Services and Public Safety for Northern Ireland Medicines and Healthcare products Regulatory Agency (MHRA) National Public Health Service for Wales NHS Confederation NHS Purchasing and Supply Agency NHS Quality Improvement Scotland Scottish Medicines Consortium Comparator manufacturers Actavis () Astellas (, butyrate) BCM Specials () Bell Sons & Co. () Biorex Laboratories () Celltech (betamethasone valerate) Co-Pharma () Derma UK (fluocinolone acetonide, fluocinonide) Dermal (, betamethasone valerate) Diomed Developments Ltd () Issue Date: September 2007 Page 1 of 7

British Association of Dermatologists British Dermatological Nursing Group British Skin Foundation Community Practitioners and Health Visitors Association National Association of Primary Care Primary Care Dermatology Society Royal College of General Practitioners Royal College of Nursing Royal College of Paediatrics and Child Health Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Intellectual Disabilities Forum United Kingdom Clinical Pharmacy Association Others Department of Health Westminster PCT Warrington PCT Welsh Assembly Government Commentators (no right to submit or appeal) Dowelhurst Ltd (betamethasone valerate) Galpharm Healthcare () GlaxoSmithKline (, betamethasone valerate, clobetasone butyrate, fluticasone propionate, clobetasol propionate) Meadow Laboratories (fluocortolone, diflucortolone valerate) Novartis Pharmaceuticals Ltd (, generic) Pliva Pharma (alclometasone dipropionate) Reckitt Benckiser Healthcare UK () Roussel Laboratories () Sandoz Ltd () Schering Plough (betamethasone dipropionate, mometasone furoate) Teva Pharmaceutical Industries Ltd (, generic) Thornton & Ross () Typharm (fludroxycortide) UCB Pharma (betamethasone valerate) Waymade () Wockhardt UK Ltd ( generic) Relevant research groups Cochrane Skin Group, Centre of Evidence-based Dermatology, University of Nottingham Policy Research Institute on Ageing and Ethnicity Skin Research Centre Skin Treatment & Research Trust The British Epidermo-Epidemiology Society Issue Date: September 2007 Page 2 of 7

Commentators (no right to submit or appeal) Assessment team Assessment group tbc National Coordinating Centre for Health Technology Assessment Associated Guideline Groups National Collaborating Centre for Women and Children Associated Public Health Groups (None) NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues. PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS Issue Date: September 2007 Page 3 of 7

Definitions: Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England. can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD). Commentators Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the British National Formulary. All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. Assessment team An independent academic group (commissioned by the NHS Research and Development Health Technology Assessment Programme [HTA Programme] to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute). Issue Date: September 2007 Page 4 of 7

Manufacturer table The matrix lists the manufacturers who have been invited to participate in a technology appraisal. As an appraisal progresses the matrix may not necessarily list all the relevant products relating to it (as manufacturers may decide that they do not wish to be involved). This table has been produced to capture all the related products for easy identification of interests for anyone involved in the topic. Manufacturer Generic Name Astellas Pharma Inc. Novartis Pharmaceuticals UK Ltd tacrolimus pimecrolimus Commentators Manufacturer Generic Name Actavis Astellas, butyrate BCM Specials Issue Date: September 2007 Page 5 of 7

Bell Sons & Co. Biorex Laboratories Celltech Co-Pharma Derma UK Dermal Diomed Pharmaceuticals Dowelhurst Ltd Galpharm Healthcare GlaxoSmithKline Meadow Laboratories Novartis Pharmaceuticals Ltd Pliva Pharma Reckitt Benckiser Healthcare UK Roussel Laboratories Sandoz Ltd Schering Plough betamethasone valerate fluocinolone acetonide, fluocinonide, betamethasone valerate betamethasone valerate, betamethasone valerate, clobetasone butyrate, fluticasone propionate, clobetasol propionate fluocortolone, diflucortolone valerate, generic alclometasone dipropionate betamethasone dipropionate, Issue Date: September 2007 Page 6 of 7

mometasone furoate Teva Pharmaceutical Industries Ltd Thornton & Ross Typharm UCB Pharma Waymade Wockhardt UK Ltd fludroxycortide betamethasone valerate generic Issue Date: September 2007 Page 7 of 7